Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NUVB Stock Forecast 2025-2026
$2.09
Current Price
$711.15M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NUVB Price Targets
+378.5%
To High Target of $10.00
+282.8%
To Median Target of $8.00
+139.2%
To Low Target of $5.00
NUVB Price Momentum
-12.2%
1 Week Change
+5.0%
1 Month Change
-35.7%
1 Year Change
-21.4%
Year-to-Date Change
-47.4%
From 52W High of $3.97
+35.7%
From 52W Low of $1.54
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Nuvation Bio (NUVB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NUVB and similar high-potential opportunities.
Latest NUVB Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, NUVB has a bullish consensus with a median price target of $8.00 (ranging from $5.00 to $10.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $2.09, the median forecast implies a 282.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Soumit Roy at Jones Trading, projecting a 378.5% upside. Conversely, the most conservative target is provided by David Nierengarten at Wedbush, suggesting a 139.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NUVB Analyst Ratings
7
Buy
0
Hold
0
Sell
NUVB Price Target Range
Low
$5.00
Average
$8.00
High
$10.00
Current: $2.09
Latest NUVB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NUVB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 23, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $6.00 |
| Mar 12, 2025 | Jones Trading | Soumit Roy | Buy | Initiates | $10.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $11.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Jan 7, 2025 | RBC Capital | Outperform | Reiterates | $0.00 | |
| Jan 6, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 7, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $6.00 |
| Oct 22, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $7.00 |
| Sep 11, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Aug 6, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $5.00 |
| Jul 17, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| May 24, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| May 22, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| May 15, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Apr 17, 2024 | RBC Capital | Kennen MacKay | Outperform | Maintains | $5.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $8.00 |
| Mar 27, 2024 | Jefferies | Michael Yee | Buy | Upgrade | $10.00 |
Nuvation Bio Inc. (NUVB) Competitors
The following stocks are similar to Nuvation Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NUVB
Nuvation Bio
mkt cap
711.15M
Nuvation Bio Inc. (NUVB) Financial Data
Nuvation Bio Inc. has a market capitalization of $711.15M with a P/E ratio of 0.0x. The company generates $10.96M in trailing twelve-month revenue with a 10.1% profit margin.
Revenue growth is +685.6% quarter-over-quarter, while maintaining an operating margin of -1,913.2% and return on equity of -119.7%.
Valuation Metrics
Market Cap
$711.15M
Enterprise Value
$260.89M
P/E Ratio
0.0x
PEG Ratio
-3.3x
Price/Sales
64.9x
Growth & Margins
Revenue Growth (YoY)
+685.6%
Gross Margin
+26.2%
Operating Margin
-1,913.2%
Net Margin
+10.1%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+64.9%
Current Ratio
9.0x
Debt/Equity
2.7x
ROE
-119.7%
ROA
-23.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nuvation Bio Inc. (NUVB) Business Model
About Nuvation Bio Inc.
What They Do
Develops innovative therapies for oncology patients.
Business Model
Nuvation Bio Inc. operates as a biopharmaceutical company that focuses on researching and advancing novel drug candidates for cancer treatment. The company generates revenue by developing next-generation therapies and bringing them through clinical trials, targeting areas with significant unmet medical needs.
Additional Information
With a strategic emphasis on challenging cancer types like neuroendocrine tumors and advanced prostate cancer, Nuvation Bio Inc. collaborates with leading oncological experts to enhance treatment options. The company's ongoing projects and breakthroughs in cancer therapy are closely monitored by investors due to their potential to significantly impact the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
273
CEO
Dr. David T. Hung M.D.
Country
United States
IPO Year
1999
Website
www.nuvationbio.comNuvation Bio Inc. (NUVB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0% and 23.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) reported its Q1 2025 financial results and is preparing for the potential U.S. approval and launch of taletrectinib for advanced ROS1-positive NSCLC.
Why It Matters
Nuvation Bio's progress toward potential U.S. approval of taletrectinib could drive stock performance and investor interest, reflecting confidence in its oncology pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio Inc. (NUVB) reported a quarterly loss of $0.16 per share, matching the Zacks Consensus Estimate, and an increase from a loss of $0.07 per share in the previous year.
Why It Matters
Nuvation Bio's quarterly loss matches expectations but worsens year-over-year, indicating potential challenges in financial performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio's taletrectinib displays a 90.1% response rate in ROS1-positive NSCLC, with FDA approval expected by June 2025. The company has over three years of cash runway but faces competitive challenges.
Why It Matters
Nuvation Bio's promising taletrectinib data and strong financial position suggest potential growth, but competition and market skepticism could impact its commercial success.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) CFO Philippe Sauvage will speak at The Citizens Life Sciences Conference on May 8, 2025, at 10 AM ET. A live webcast will be available on their website.
Why It Matters
Nuvation Bio's CFO participation in a prominent conference signals potential insights into the company's financial health and oncology developments, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
20 days ago
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) will announce Q1 2025 results on May 7, 2025, at 4:30 p.m. ET, discussing programs, taletrectinib's commercial strategy, and financial results.
Why It Matters
Nuvation Bio's upcoming earnings call will reveal insights into its oncology programs and financial health, with a focus on taletrectinib's FDA status, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) executives will speak at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 10:00 a.m. PT in Las Vegas, NV.
Why It Matters
Nuvation Bio's participation in a key industry conference highlights its commitment to oncology, potentially boosting investor confidence and interest in its future developments and strategies.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NUVB Stock
What is Nuvation Bio Inc.'s (NUVB) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Nuvation Bio Inc. (NUVB) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $5.00.
Is NUVB stock a good investment in 2025?
According to current analyst ratings, NUVB has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NUVB stock?
Wall Street analysts predict NUVB stock could reach $8.00 in the next 12 months. This represents a 282.8% increase from the current price of $2.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvation Bio Inc.'s business model?
Nuvation Bio Inc. operates as a biopharmaceutical company that focuses on researching and advancing novel drug candidates for cancer treatment. The company generates revenue by developing next-generation therapies and bringing them through clinical trials, targeting areas with significant unmet medical needs.
What is the highest forecasted price for NUVB Nuvation Bio Inc.?
The highest price target for NUVB is $10.00 from Soumit Roy at Jones Trading, which represents a 378.5% increase from the current price of $2.09.
What is the lowest forecasted price for NUVB Nuvation Bio Inc.?
The lowest price target for NUVB is $5.00 from David Nierengarten at Wedbush, which represents a 139.2% increase from the current price of $2.09.
What is the overall NUVB consensus from analysts for Nuvation Bio Inc.?
The overall analyst consensus for NUVB is bullish. Out of 10 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are NUVB stock price projections?
Stock price projections, including those for Nuvation Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 10:25 AM UTC